Zhang Xinyu, Cao Chao, Zheng Fei, Liu Chang, Tian Xiuqing
Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, 16766 Jingshi Road, Jinan City, 250014, China.
Shandong First Medical University (Shandong Academy of Medical Sciences), 6699 Qingdao Road, Jinan City, 250117, China.
Cardiovasc Drugs Ther. 2025 Jan 20. doi: 10.1007/s10557-025-07670-9.
Glucagon-like peptide-1 (GLP-1) is a crucial incretin hormone secreted by intestinal endocrine L cells. Given its pivotal physiological role, researchers have developed GLP-1 receptor agonists (GLP-1 RAs) through structural modifications. These analogues display pharmacological effects similar to those of GLP-1 but with augmented stability and are regarded as an effective means of regulating blood glucose levels in clinical practice.
This review aims to comprehensively summarize the role of GLP-1 RAs in the management of diabetes mellitus (DM) and cardiovascular disease (CVD), with a particular emphasis on the underlying signal transduction pathways and their therapeutic potential.
A comprehensive review was carried out through literature research.
In pancreatic β-cells, GLP-1 RAs regulate the secretion of insulin and glucagon in a glucosedependent manner by influencing signaling pathways such as cAMP, PI3K, and MAPK. They also contribute to the regulation of blood glucose levels by promoting the proliferation of β-cells and inhibiting apoptosis in these cells. Recent comprehensive studies have also demonstrated the favorable impact of GLP-1 RAs on cardiovascular wellbeing. In addition to the cardiovascular protection afforded by glucose metabolism regulation, a large body of evidence from animal and cellular studies has corroborated the beneficial effects of GLP-1 RAs on conditions such as heart failure (HF), hypertension, and ischemic cardiomyopathy. These benefits are mainly attributed to the alleviation of inflammatory responses, reduction of oxidative stress, and prevention of cell apoptosis. Clinical data shows that GLP-1 RAs can reduce the risk of major adverse cardiovascular events (MACE) in diabetic patients.
GLP-1 RAs play an important role in the management of both diabetes and cardiovascular diseases. They show potential therapeutic value through the modulation of multiple signal transduction pathways. However, there may still be some issues in practical applications that require further research and resolution.
胰高血糖素样肽-1(GLP-1)是肠道内分泌L细胞分泌的一种关键肠促胰岛素激素。鉴于其关键的生理作用,研究人员通过结构修饰开发了GLP-1受体激动剂(GLP-1 RAs)。这些类似物表现出与GLP-1相似的药理作用,但稳定性增强,在临床实践中被视为调节血糖水平的有效手段。
本综述旨在全面总结GLP-1 RAs在糖尿病(DM)和心血管疾病(CVD)管理中的作用,特别强调潜在的信号转导途径及其治疗潜力。
通过文献研究进行全面综述。
在胰腺β细胞中,GLP-1 RAs通过影响cAMP、PI3K和MAPK等信号通路,以葡萄糖依赖的方式调节胰岛素和胰高血糖素的分泌。它们还通过促进β细胞增殖和抑制这些细胞的凋亡,有助于调节血糖水平。最近的综合研究还证明了GLP-1 RAs对心血管健康的有利影响。除了通过调节葡萄糖代谢提供心血管保护外,大量动物和细胞研究的证据证实了GLP-1 RAs对心力衰竭(HF)、高血压和缺血性心肌病等病症的有益作用。这些益处主要归因于炎症反应的减轻、氧化应激的降低和细胞凋亡的预防。临床数据表明,GLP-1 RAs可降低糖尿病患者发生主要不良心血管事件(MACE)的风险。
GLP-1 RAs在糖尿病和心血管疾病的管理中发挥着重要作用。它们通过调节多种信号转导途径显示出潜在的治疗价值。然而,在实际应用中可能仍存在一些问题,需要进一步研究和解决。